The Senolytics Pipeline in 2026: Where the Science Still Looks Strong — and Where It Doesn’t
Few ideas in longevity science remain as intuitively powerful as senolytics. If aging tissues accumulate senescent cells — damaged cells […]
Therapeutics
Are GLP-1s the First Longevity Drugs — or Just the First Big Proxy?
Few drug classes have moved from endocrinology into so many neighboring territories so quickly. What began as a diabetes story